Search Results

Business

Repligen Appoints Maggie A. Pax to Board of Directors

Repligen Corporation announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

March 19, 2024

·

4 min read

Pharm Country

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin.

April 11, 2024

·

5 min read

Drug Development

PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection

August 27, 2024

·

6 min read

Business

Alimera Appoints Maggie A. Pax to Its Board of Directors

Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces the addition of Maggie A. Pax to its Board of Directors.

November 8, 2023

·

3 min read

Pharm Country

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders.

May 7, 2024

·

4 min read

Deals

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

PaxMedica, Inc. today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq Hearings Panel to delist the Company from Nasdaq.

May 15, 2024

·

5 min read

Pharm Country

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

PaxMedica Inc., a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health of Malawi, a country in east Africa.

April 23, 2024

·

4 min read

Biotech Bay

Novel Research by PAX and Zentrela Suggests Cannabis “Entourage Effect,” Not THC Potency, Responsible for Psychoactive Experience

PAX, a leading global cannabis brand, today announced a collaboration with pioneering Canadian neurotechnology company, Zentrela, leveraging brainwave research to provide consumers with data-driven insight into cannabis effects — ultimately supporting more informed purchasing and consumption decisions.

October 3, 2023

·

3 min read

Drug Development

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

PaxMedica, Inc. today announced positive top line data for the Company’s PAX-HAT-301 Retrospective Analysis of Suramin Treatment for Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (S1 TBR HAT).

July 24, 2023

·

10 min read

Illustration showing male, female choosing from three paths

Career Advice

12 Careers for Ph.D. Life Scientists Outside of the Lab

Not everyone who completes a life sciences Ph.D. wants to continue working in a laboratory or in research. If this is the case for you, here are 12 careers for Ph.D. life scientists outside of the lab.

November 5, 2024

·

5 min read

·

Mark Terry